RAPP · Insider Trading
Rapport Therapeutics, Inc. Common Stock
Every open-market purchase and sale reported by RAPP officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-23 | Ramiro Sanchez | Director | Buy | +3,600 | +$98.48K |
| 2026-10-23 | Abraham Ceesay | Chief Executive Officer | Sell | −2,210 | −$64.45K |
| 2026-10-22 | Paul M Silva | Director | Buy | +3,680 | +$99.64K |
| 2026-10-22 | Wendy B. Young | Director | Buy | +3,789 | +$99.99K |
| 2026-10-22 | Steven M Paul | Director | Buy | +35,714 | +$974.28K |
| 2026-10-22 | John Maraganore | Director | Buy | +9,411 | +$248.89K |
| 2026-10-21 | Troy A. Ignelzi | Chief Financial Officer | Buy | +5,500 | +$143.55K |
| 2026-10-08 | Abraham Ceesay | Chief Executive Officer | Sell | −4,522 | −$143.27K |
| 2026-10-01 | Cheryl Gault | Chief Operating Officer | Sell | −10,000 | −$331.86K |
| 2026-09-24 | Abraham Ceesay | Chief Executive Officer | Sell | −2,210 | −$86.57K |
| 2026-09-09 | Abraham Ceesay | Chief Executive Officer | Sell | −8,210 | −$374.50K |
| 2026-08-26 | Abraham Ceesay | Chief Executive Officer | Sell | −18,921 | −$937.96K |
| 2026-08-26 | Krishnaswamy Yeleswaram | Chief Development Officer | Sell | −50,160 | −$2.53M |
| 2026-08-20 | Krishnaswamy Yeleswaram | Chief Development Officer | Sell | −404 | −$20.16K |
| 2026-08-12 | Abraham Ceesay | Chief Executive Officer | Sell | −51,499 | −$2.43M |
| 2026-07-29 | Abraham Ceesay | Chief Executive Officer | Sell | −2,210 | −$93.06K |
| 2026-07-15 | Abraham Ceesay | Chief Executive Officer | Sell | −8,210 | −$328.44K |
| 2026-07-01 | Abraham Ceesay | Chief Executive Officer | Sell | −8,220 | −$327.40K |
| 2026-07-01 | Cheryl Gault | Chief Operating Officer | Sell | −10,000 | −$415.80K |
| 2026-06-10 | Wendy B. Young | Director | A | +15,200 deriv. | — |
| 2026-06-10 | Robert J Perez | Director | A | +15,200 deriv. | — |
| 2026-06-10 | James Healy | Director | A | +15,200 deriv. | — |
| 2026-06-10 | Reid M Huber | Director | A | +15,200 deriv. | — |
| 2026-06-10 | Ramiro Sanchez | Director | A | +15,200 deriv. | — |
| 2026-06-10 | Steven M Paul | Director | A | +15,200 deriv. | — |
| 2026-06-10 | John Maraganore | Director | A | +15,200 deriv. | — |
| 2026-06-10 | Paul M Silva | Director | A | +15,200 deriv. | — |
| 2026-05-28 | Third Rock Ventures GP VI, L.P. | 10%+ Owner | Sell | −111,432 | −$4.46M |
| 2026-05-13 | TRV GP V, LLC | 10%+ Owner | Sell | −801,708 | −$32.26M |
| 2026-05-11 | Third Rock Ventures VI, L.P. | 10%+ Owner | Sell | −1,659,078 | −$66.57M |
| 2026-04-21 | Krishnaswamy Yeleswaram | Chief Development Officer | Sell | −20,225 | −$808.84K |
| 2026-04-21 | Third Rock Ventures V, L.P. | 10%+ Owner | Sell | −2,556,030 | −$103.05M |
| 2026-04-14 | Krishnaswamy Yeleswaram | Chief Development Officer | Sell | −19,865 | −$695.82K |
| 2026-04-09 | Krishnaswamy Yeleswaram | Chief Development Officer | Sell | −360 | −$12.56K |
| 2026-03-26 | Krishnaswamy Yeleswaram | Chief Development Officer | Sell | −10,115 | −$303.35K |
| 2026-03-09 | Cheryl Gault | Chief Operating Officer | Sell | −2,014 | −$58.27K |
| 2026-02-19 | David Bredt | Chief Scientific Officer | MIXED | −2,500 | −$235.86K |
| 2026-02-19 | Abraham Ceesay | Chief Executive Officer | Sell | −10,916 | −$320.37K |
| 2026-02-04 | David Bredt | Chief Scientific Officer | A | +103,000 deriv. | — |
| 2026-02-04 | Krishnaswamy Yeleswaram | Chief Development Officer | A | +120,000 deriv. | — |
| 2026-02-04 | Troy A. Ignelzi | Chief Financial Officer | A | +148,000 deriv. | — |
| 2026-02-04 | Abraham Ceesay | Chief Executive Officer | A | +428,000 deriv. | — |
| 2026-02-04 | Cheryl Gault | Chief Operating Officer | A | +132,000 deriv. | — |
| 2026-02-04 | Jeffrey Sevigny | Chief Medical Officer | A | +130,000 deriv. | — |
| 2026-01-22 | Abraham Ceesay | Chief Executive Officer | Sell | −10,916 | −$285.07K |
| 2026-01-16 | David Bredt | Chief Scientific Officer | Sell | −8,500 | −$228.13K |
| 2026-01-05 | Krishnaswamy Yeleswaram | Chief Development Officer | MIXED | +6,160 | −$85.34K |
| 2026-01-05 | David Bredt | Chief Scientific Officer | MIXED | −24,567 | −$197.34K |
| 2025-12-18 | Abraham Ceesay | Chief Executive Officer | Sell | −10,916 | −$323.51K |
| 2025-12-16 | David Bredt | Chief Scientific Officer | Sell | −8,500 | −$255.13K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Third Rock Ventures V, L.P. | 10%+ Owner | 7,678,446 | $194.50M |
| Third Rock Ventures VI, L.P. | 10%+ Owner | 7,406,951 | $187.62M |
| TRV GP V, LLC | 10%+ Owner | 7,268,315 | $184.11M |
| Third Rock Ventures GP VI, L.P. | 10%+ Owner | 7,249,743 | $183.64M |
| Steven M Paul | Director | 555,022 | $14.06M |
| Abraham Ceesay | Chief Executive Officer | 531,764 | $13.47M |
| David Bredt | Chief Scientific Officer | 389,275 | $9.86M |
| Krishnaswamy Yeleswaram | Chief Development Officer | 212,063 | $5.37M |
| Cheryl Gault | Chief Operating Officer | 141,989 | $3.60M |
| James Healy | Director | 39,661 | $1.00M |
| Reid M Huber | Director | 20,400 | $516.73K |
| Troy A. Ignelzi | Chief Financial Officer | 15,500 | $392.62K |
| Wendy B. Young | Director | 13,289 | $336.61K |
| John Maraganore | Director | 8,239 | $208.69K |
| Paul M Silva | Director | 3,680 | $93.21K |
| Ramiro Sanchez | Director | 3,600 | $91.19K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the RAPP quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.